Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding.
作者信息
Ganjehei Leila, Wilson James M
机构信息
Department of Adult Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
出版信息
Tex Heart Inst J. 2012;39(4):517-25.
Abstract
摘要
相似文献
1
Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding.非瓣膜性心房颤动患者预防卒中的抗凝药物：新药物及最新认识
Tex Heart Inst J. 2012;39(4):517-25.
2
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.新型口服抗凝剂用于心房颤动患者的疗效及安全性比较
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.
3
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动患者预防卒中的阿司匹林、华法林和新型抗凝药的混合治疗比较荟萃分析。
Clin Ther. 2013 Jul;35(7):967-984.e2. doi: 10.1016/j.clinthera.2013.05.011.
4
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.房颤卒中预防的治疗方法：网状荟萃分析和间接比较与达比加群酯。
Thromb Haemost. 2010 Dec;104(6):1106-15. doi: 10.1160/TH10-10-0642. Epub 2010 Oct 21.
5
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.非瓣膜性心房颤动患者口服抗凝剂的有效性和安全性。
Stroke. 2018 Dec;49(12):2933-2944. doi: 10.1161/STROKEAHA.118.020232.
6
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
7
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.伴有单一卒中危险因素的房颤患者中标准剂量非维生素 K 拮抗剂口服抗凝剂和华法林的有效性和安全性：一项全国性队列研究。
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
8
Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.新型口服抗凝剂在非瓣膜性心房颤动卒中预防中的应用的实际考虑。
Cardiovasc Ther. 2014 Apr;32(2):74-81. doi: 10.1111/1755-5922.12048.
9
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?ARISTOTLE 再研究 （RE-LYs） 火箭试验。心房颤动患者卒中预防有何新进展？
Cardiol J. 2012;19(1):4-10. doi: 10.5603/cj.2012.0002.
10
The new era of anticoagulation.抗凝治疗的新时代。
Ann Vasc Surg. 2014 Feb;28(2):503-14. doi: 10.1016/j.avsg.2013.07.013. Epub 2013 Oct 1.
本文引用的文献
1
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.在随机评估长期抗凝治疗试验（RE-LY 试验）中，达比加群或华法林与抗血小板治疗同时使用。
Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
2
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.利伐沙班、乙酰水杨酸和氯吡格雷单药及联合治疗在猪支架血栓形成模型中的作用。
J Thromb Haemost. 2012 Dec;10(12):2470-80. doi: 10.1111/jth.12033.
3
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.心房颤动合并冠状动脉疾病患者的抗凝和抗血小板治疗。
Thrombosis. 2012;2012:184573. doi: 10.1155/2012/184573. Epub 2012 Apr 23.
4
Rivaroxaban in patients with a recent acute coronary syndrome.利伐沙班用于近期急性冠状动脉综合征患者。
N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.
5
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.在健康受试者中，用凝血酶原复合物浓缩物逆转利伐沙班和达比加群：一项随机、安慰剂对照、交叉研究。
Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.
6
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
7
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
8
Apixaban with antiplatelet therapy after acute coronary syndrome.急性冠脉综合征后应用阿哌沙班联合抗血小板治疗。
N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.
9
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.与华法林相比，达比加群酯在老年和年轻房颤患者中使用 2 剂的出血风险：随机长期抗凝治疗评估（RE-LY）试验分析。
Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
10
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.抗 Xa 治疗降低急性冠状动脉综合征患者心血管事件的作用及标准治疗的附加作用（血栓溶解治疗急性心肌梗死 51 研究）的研究原理和设计：一项评估利伐沙班在急性冠状动脉综合征患者中的疗效和安全性的随机、双盲、安慰剂对照研究。
Am Heart J. 2011 May;161(5):815-821.e6. doi: 10.1016/j.ahj.2011.01.026.
Zotero 插件